ES2153665T3 - Usos terapeuticos de productos proteicos bactericidas/incrementadores de la permeabilidad (bpi) para la meningococemia humana. - Google Patents

Usos terapeuticos de productos proteicos bactericidas/incrementadores de la permeabilidad (bpi) para la meningococemia humana.

Info

Publication number
ES2153665T3
ES2153665T3 ES97924679T ES97924679T ES2153665T3 ES 2153665 T3 ES2153665 T3 ES 2153665T3 ES 97924679 T ES97924679 T ES 97924679T ES 97924679 T ES97924679 T ES 97924679T ES 2153665 T3 ES2153665 T3 ES 2153665T3
Authority
ES
Spain
Prior art keywords
human
bpi
meningococemia
incrementers
bactericide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97924679T
Other languages
English (en)
Inventor
Brett P Giroir
Patrick J Scannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Xoma Technology Ltd USA
University of Texas at Austin
Original Assignee
University of Texas System
Xoma Technology Ltd USA
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, Xoma Technology Ltd USA, University of Texas at Austin filed Critical University of Texas System
Application granted granted Critical
Publication of ES2153665T3 publication Critical patent/ES2153665T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PROPORCIONAN PROCEDIMIENTOS Y MATERIALES PARA EL TRATAMIENTO DE LA MENINGOCOCEMIA HUMANA, EN LOS QUE SE ADMINISTRAN CANTIDADES TERAPEUTICAMENTE EFECTIVAS DE PRODUCTOS DE PROTEINAS BPI.
ES97924679T 1996-05-10 1997-05-09 Usos terapeuticos de productos proteicos bactericidas/incrementadores de la permeabilidad (bpi) para la meningococemia humana. Expired - Lifetime ES2153665T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64428796A 1996-05-10 1996-05-10

Publications (1)

Publication Number Publication Date
ES2153665T3 true ES2153665T3 (es) 2001-03-01

Family

ID=24584256

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97924679T Expired - Lifetime ES2153665T3 (es) 1996-05-10 1997-05-09 Usos terapeuticos de productos proteicos bactericidas/incrementadores de la permeabilidad (bpi) para la meningococemia humana.

Country Status (14)

Country Link
US (4) US5888977A (es)
EP (1) EP0914144B1 (es)
JP (1) JP2000510845A (es)
CN (1) CN1236320A (es)
AT (1) ATE198050T1 (es)
AU (1) AU735058B2 (es)
CA (1) CA2253837C (es)
DE (1) DE69703689T2 (es)
DK (1) DK0914144T3 (es)
ES (1) ES2153665T3 (es)
GR (1) GR3035440T3 (es)
NZ (2) NZ505070A (es)
PT (1) PT914144E (es)
WO (1) WO1997042966A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US6214789B1 (en) * 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US6464700B1 (en) 1994-10-07 2002-10-15 Scimed Life Systems, Inc. Loop structures for positioning a diagnostic or therapeutic element on the epicardium or other organ surface
US6071274A (en) 1996-12-19 2000-06-06 Ep Technologies, Inc. Loop structures for supporting multiple electrode elements
WO1997004008A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
DE69703689T2 (de) * 1996-05-10 2001-05-10 Xoma Technology Ltd., Berkeley Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6048329A (en) * 1996-12-19 2000-04-11 Ep Technologies, Inc. Catheter distal assembly with pull wires
US6203525B1 (en) 1996-12-19 2001-03-20 Ep Technologies, Inc. Catheterdistal assembly with pull wires
US6071279A (en) 1996-12-19 2000-06-06 Ep Technologies, Inc. Branched structures for supporting multiple electrode elements
US6332880B1 (en) 1996-12-19 2001-12-25 Ep Technologies, Inc. Loop structures for supporting multiple electrode elements
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6610055B1 (en) 1997-10-10 2003-08-26 Scimed Life Systems, Inc. Surgical method for positioning a diagnostic or therapeutic element on the epicardium or other organ surface
EP2261338A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
NZ513087A (en) * 1999-01-22 2003-02-28 Xoma Technology Ltd Bactericidal/permability -increasing protein (BPI) for treating chronic heart disease
US6217528B1 (en) 1999-02-11 2001-04-17 Scimed Life Systems, Inc. Loop structure having improved tissue contact capability
US6613046B1 (en) 1999-11-22 2003-09-02 Scimed Life Systems, Inc. Loop structures for supporting diagnostic and therapeutic elements in contact with body tissue
US6542781B1 (en) 1999-11-22 2003-04-01 Scimed Life Systems, Inc. Loop structures for supporting diagnostic and therapeutic elements in contact with body tissue
US6645199B1 (en) 1999-11-22 2003-11-11 Scimed Life Systems, Inc. Loop structures for supporting diagnostic and therapeutic elements contact with body tissue and expandable push devices for use with same
US6529756B1 (en) 1999-11-22 2003-03-04 Scimed Life Systems, Inc. Apparatus for mapping and coagulating soft tissue in or around body orifices
WO2001078803A1 (en) * 2000-04-14 2001-10-25 Biotime, Inc. Systems, kits, and methods of administering synthetic plasma
US20020173464A1 (en) * 2000-12-01 2002-11-21 King George L. Modulation of pericyte proliferation
EP1741440A1 (en) 2005-07-08 2007-01-10 Mellitus S.L. Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
WO2009126833A2 (en) * 2008-04-09 2009-10-15 Microlin, Llc Transdermal oxygen delivery apparatus and method
DE102010015682B4 (de) 2010-04-21 2014-01-02 Peter Arnold Vorrichtung zum Erfassen der Prozessstrahlung bei der Lasermaterialbearbeitung
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245013A (en) * 1985-04-30 1993-09-14 Richard Ulevitch Acute phase protein modulating endotoxic activity of lipopolysaccharides, assay methods and polypeptides
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
DK0485430T3 (da) * 1989-08-01 1999-06-14 Scripps Research Inst Fremgangsmåder og sammensætninger til bedring af symptomer på sepsis
EP0563222B1 (en) * 1990-12-03 1998-02-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
WO1993006228A1 (en) * 1991-09-26 1993-04-01 Incyte Pharmaceuticals, Inc. A new form of liposaccharide binding protein (lbp)
AU669723B2 (en) * 1992-05-19 1996-06-20 Xoma Corporation Improved methods for the preparation of endotoxin-binding proteins
US5643570A (en) * 1992-05-19 1997-07-01 Xoma Corporation BPI-immunoglobulin fusion proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物
JPH08509703A (ja) * 1993-03-12 1996-10-15 ゾーマ コーポレイション 殺菌／透過性増加タンパク質産物の治療用途
CA2157925C (en) * 1993-03-12 2000-06-06 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
ES2123134T3 (es) * 1993-03-12 1999-01-01 Xoma Corp Peptidos biologicamente activos de dominios funcionales de la proteina bactericida aumentadora de la permeabilidad y usos de los mismos.
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
AU6522794A (en) * 1993-03-22 1994-10-11 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein and lipopolysaccharide binding protein levels and ratios thereof in diagnosis
EP0760849A1 (en) * 1993-04-30 1997-03-12 Incyte Pharmaceuticals, Inc. Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
WO1995000641A1 (en) * 1993-06-17 1995-01-05 Xoma Corporation Lipopolysaccharide binding protein derivatives
WO1995001428A1 (en) * 1993-07-02 1995-01-12 Incyte Pharmaceuticals, Inc. Glycosylated and non-glycosylated bactericidal/permeability increasing proteins, and methods for producing same
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
US5466580A (en) * 1993-09-22 1995-11-14 Xoma Corporation Method for quantifying BPI in body fluids
PT759774E (pt) * 1993-09-22 2002-11-29 Xoma Technology Ltd Metodo para o tratamento de infeccoes bacterianas gram-negativas por administracao de um produto de proteina bactericida indutora da permeabilidade (bip) e de um antibiotico
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
CA2173611C (en) * 1993-10-05 2005-07-26 Paul A. M. Van Leeuwen Method of treating depressed reticuloendothelial system function
ATE219684T1 (de) * 1994-01-14 2002-07-15 Xoma Technology Ltd Anti gram positive bakterielle verfahren und mittel
MX9602570A (es) * 1994-01-14 1997-04-30 Xoma Corp Metodos y materiales anti-fungosos.
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5532216A (en) * 1994-06-24 1996-07-02 Incyte Pharmaceuticals, Inc. Neutralization of non-lipopolysaccharide compounds by bactericidal/permeability-increasing protein
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
ATE256147T1 (de) * 1994-09-15 2003-12-15 Xoma Technology Ltd Peptide gegen pilzen
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
DE69703689T2 (de) * 1996-05-10 2001-05-10 Xoma Technology Ltd., Berkeley Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
GB2316940A (en) 1996-08-30 1998-03-11 Queen Mary & Westfield College Silicon-substituted hydroxyapatite

Also Published As

Publication number Publication date
DE69703689T2 (de) 2001-05-10
US6596691B2 (en) 2003-07-22
DE69703689D1 (de) 2001-01-18
US6242418B1 (en) 2001-06-05
CN1236320A (zh) 1999-11-24
DK0914144T3 (da) 2001-04-09
EP0914144A1 (en) 1999-05-12
US5888977A (en) 1999-03-30
EP0914144B1 (en) 2000-12-13
PT914144E (pt) 2001-05-31
CA2253837C (en) 2002-07-02
NZ505070A (en) 2005-01-28
US20020103114A1 (en) 2002-08-01
US5990086A (en) 1999-11-23
NZ332720A (en) 2000-07-28
CA2253837A1 (en) 1997-11-20
JP2000510845A (ja) 2000-08-22
ATE198050T1 (de) 2000-12-15
AU3004397A (en) 1997-12-05
WO1997042966A1 (en) 1997-11-20
GR3035440T3 (en) 2001-05-31
AU735058B2 (en) 2001-06-28
HK1019856A1 (en) 2000-03-03

Similar Documents

Publication Publication Date Title
ES2153665T3 (es) Usos terapeuticos de productos proteicos bactericidas/incrementadores de la permeabilidad (bpi) para la meningococemia humana.
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
FI963696A7 (fi) Geeli ihosairauksien hoitoon ja ihon desinfiointiin
FI973468L (fi) Hampaiden valkaisemiseen tai ihon ja limakalvojen sairauksien hoitoon käytettävien valmisteiden valmistusmenetelmä
BR9006924A (pt) Formulacao para tratamento de sintomas e doencas,uso de formulacao para o tratamento de sintomas e doencas,metodo para o tratamento de sintomas e doencas,distribuicao de agentes medicinais e terapeuticos para o tratamento de sintomas e doencas e combinacao para administracao em mamiferos
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
NO994014L (no) Arylsulfonamider og analoger derav og deres anvendelse for behandling av neurodegenerative sykdommer
ES2060310T3 (es) Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion.
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
DE69727142D1 (de) Verwendung eines bpi proteinproduktes als antithrombotisches mittel
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
PT928193E (pt) Utilizacao de 1-hidroxi-2-piridonas para o tratamento de infeccoes da pele
PT900563E (pt) Producao de formulacoes farmaceuticas para o tratamento de edema e doencas venosas
FI956353L (fi) Farmaseuttiset valmisteet ja niiden käyttö etenkin neurodegeneratiivisten sairauksien hoidossa
PT983300E (pt) Sais peptidicos de bpc com actividade organo-protectora, processo para a sua preparacao e sua utilizacao em terapia
ATE238796T1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
FI950649L (fi) Substituoidut sykloheksanoliesterit, niiden käyttö sairauksien hoitamiseksi ja farmaseuttiset valmisteet
BR9708037A (pt) Método para o tratamento de abuso de substância
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
FI961494L (fi) Farmaseuttisia koostumuksia ja niiden käyttö, etenkin hermoston rappeutumissairauksien hoitamiseksi
FI972637A0 (fi) K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon
PT999849E (pt) Utilizacao de lbp no tratamento da septicemia
ITRM960808A0 (it) Immunoconiugati comprendenti anticorpi monoclonali umani o frammenti di essi per diagnosi in vivo e terapia
ITRM940453A0 (it) "uso della proteina p1lsa per la preparazione di un medicamento da utilizzarsi nella terapia di patologie indotte da danni cellulari da agenti fisici, chimici o biologici"

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 914144

Country of ref document: ES